The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Code of Practice was first created in 1981 and is part of a decades-long commitment to promoting ethical practices in the pharmaceutical industry. The goal is to ensure that practices in the pharmaceutical industry are governed by ethical standards in line with societal expectations.

The Code has been revised six times since its inception. The current IFPMA Code of Practice came into effect on 1st January 2019, with the following changes compared to previous versions:

Peru’s Ministry of Economy and Finance has approved a new Code of Ethics and Conduct as part of its efforts to combat corruption and promote ethical principles and moral values.

The Code was co-developed by ministry officials with technical assistance from SECO-funded Public Finance Management programme implemented by the Basel Institute on Governance in Peru. 

Peru’s Ministry of Economy and Finance co-developed a new Code of Ethics and Conduct as part of its efforts to combat corruption and promote ethical principles and moral values.

The Code was collaboratively developed by ministry officials with technical assistance from SECO-funded Public Finance Management programme implemented by the Basel Institute on Governance in Peru. 

An expert from the International Centre for Asset Recovery, a part of the Basel Institute on Governance, visited Mozambique between 10-14 October with a view to conduct an on-site assessment of the anti-corruption legislative package that had been proposed by the Council of Ministers to the Assembly of the Republic. The project, jointly financed by USAID and DfID, sought to assess the impact of the package in the Mozambican legal system, as well as to benchmark it with the international and regional standards on preventing and combating corruption.